Disclosed a robust net order book for electric buses, totaling 8,088 units, with significant demand continuing, including orders from MSRTC for 5,150 buses.

Earnings per share rose to Rs. 39.90 in Q3 FY24 from Rs. 36.90 in Q3 FY23 on a consolidated basis. The trading volumes exhibited significant growth, with cash markets recording an average daily traded volume (ADTV) of Rs. 80,512 crores (up 50 per cent YoY), equity futures reaching an ADTV of Rs. 1,31,010 crores (up 18 per cent YoY), and equity options (premium value) ADTVs standing at Rs. 56,707 crores (up 28 per cent YoY) for Q3 FY24.

Of significant note is the remarkable reduction in the company's debt-to-EBITDA ratio, which has undergone a substantial decline from 5.7x in FY'22 to 2.8x on an annualized quarterly basis, signaling a notable financial transformation. Despite surpassing guidance in debt reduction, the company continues to generate free cash flow

Furthermore, the operating profit stood at Rs 29 crore, while the net profit exhibited an impressive YoY doubling, ascending to Rs 12 crore from Rs 5 crore in Q3FY23.

Now with market timing extension, they are worried that their backtest won’t be relevant anymore. Such scenarios always happen.

Company  boasts an impressive order book as of December 31, 2023, exceeding Rs 4800 crore, with expectations of further inflows ranging between Rs 4000 to 5000 crore. Notably, the company's stock has delivered multibagger returns over the past year, skyrocketing by an astounding 256 per cent, making it a compelling candidate to keep on your radar.

An intriguing development surrounding the stock pertains to its Foreign Institutional Investors (FIIs) holding, which surged to a record high of 1.98 per cent as per the shareholding pattern for the December 2023 quarter, up from the previous figure of 0.50 per cent.

However, as the issue progressed, a cloud of uncertainty descended. Despite an overwhelming response (received subscription for 1,43,31,856 equity shares, which is 118.35 per cent of the issue size) from eager investors, the company found itself falling short of the minimum subscription threshold of 90 per cent. How could this be?

At the start of the year, the company has found itself at the center of attention as 25 entities, including notable names like Sheth Developers and Sunteck Realty, have expressed keen interest in acquiring the beleaguered company, which has been mired in bankruptcy proceedings.

In this landscape of innovation, companies like Laurus Lab Ltd stand out as key players driving progress in the transformative cell and gene therapy space. Their strategic collaborations and advancements in product development hold promise for improving treatment outcomes and enhancing accessibility for patients